Press Releases April 7, 2026 08:00 PM

BOSS Zhipin Continues Share Repurchases, with Total Repurchases Amounting to Nearly RMB721 Million in 2026

KANZHUN LIMITED Continues Aggressive Share Buyback Program in 2026, Reflecting Strong Commitment to Shareholder Value

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
BZ

KANZHUN LIMITED, operating as BOSS Zhipin, announced ongoing share repurchases totaling nearly RMB721 million so far in 2026, including a recent purchase of approximately RMB27.3 million for 603,724 shares. The program highlights the company's dedication to enhancing shareholder returns.

BOSS Zhipin Continues Share Repurchases, with Total Repurchases Amounting to Nearly RMB721 Million in 2026
BZ
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • KANZHUN LIMITED has executed share repurchases worth nearly RMB721 million year-to-date in 2026.
  • On April 7, 2026, the company repurchased 603,724 ordinary shares for RMB27.3 million.
  • The buyback program signals management's confidence in the company's valuation and a commitment to returning value to shareholders.

BEIJING, April 08, 2026 (GLOBE NEWSWIRE) -- KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ; HK: 2076) today announced the continued execution of its share repurchase program, utilizing around RMB27.3 million to repurchase 603,724 ordinary shares on April 7. Year-to-date in 2026, the Company has deployed nearly RMB721 million toward share repurchases. This move underscores the Company's ongoing commitment to shareholder returns.


Risks

  • Continued large-scale share repurchases may strain company cash flow or limit funds for growth initiatives.
  • Market conditions or regulatory changes in China or the U.S. could impact the company's operational performance or stock price.
  • Uncertainty related to the company’s future earnings growth might affect market perception despite buybacks.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026